- Home
- BANC vs ZLAB Comparison
BANC vs ZLAB Comparison
Compare BANC & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANC
- ZLAB
- Stock Information
- Founded
- BANC 1941
- ZLAB 2013
- Country
- BANC United States
- ZLAB China
- Employees
- BANC N/A
- ZLAB N/A
- Industry
- BANC Major Banks
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- BANC Finance
- ZLAB Health Care
- Exchange
- BANC Nasdaq
- ZLAB Nasdaq
- Market Cap
- BANC 2.5B
- ZLAB 1.8B
- IPO Year
- BANC N/A
- ZLAB 2017
- Fundamental
- Price
- BANC $15.81
- ZLAB $31.24
- Analyst Decision
- BANC Buy
- ZLAB Strong Buy
- Analyst Count
- BANC 11
- ZLAB 4
- Target Price
- BANC $17.27
- ZLAB $52.50
- AVG Volume (30 Days)
- BANC 2.2M
- ZLAB 976.3K
- Earning Date
- BANC 10-22-2024
- ZLAB 11-12-2024
- Dividend Yield
- BANC 2.54%
- ZLAB N/A
- EPS Growth
- BANC N/A
- ZLAB N/A
- EPS
- BANC N/A
- ZLAB N/A
- Revenue
- BANC $412,570,000.00
- ZLAB $322,711,000.00
- Revenue This Year
- BANC N/A
- ZLAB $48.34
- Revenue Next Year
- BANC $9.72
- ZLAB $47.12
- P/E Ratio
- BANC N/A
- ZLAB N/A
- Revenue Growth
- BANC N/A
- ZLAB 28.16
- 52 Week Low
- BANC $10.81
- ZLAB $13.48
- 52 Week High
- BANC $15.86
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- BANC 65.16
- ZLAB 70.41
- Support Level
- BANC $15.20
- ZLAB $31.52
- Resistance Level
- BANC $15.69
- ZLAB $36.60
- Average True Range (ATR)
- BANC 0.43
- ZLAB 1.36
- MACD
- BANC 0.10
- ZLAB 0.34
- Stochastic Oscillator
- BANC 97.95
- ZLAB 58.60
About BANC Banc of California Inc.
Banc of California Inc is a financial holding company. It offers banking and financial services. The company's services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.